P63 immunohistochemistry is a useful adjunct in distinguishing sclerosing cutaneous tumors

American Journal of Dermatopathology

Volumn 32, Issue 3, 2010, Pages 257-261

  Vidal, Claudia I ^a   Goldberg, Matthew ^a   Burstein, David E ^a   Emanuel, Henry J ^b   Emanuel, Patrick O ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

Adnexal tumor; Immunohistochemistry; P63

Indexed keywords

PROTEIN P63;

ADNEXA DISEASE; ARTICLE; BASAL CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN TUMOR; TRICHOEPITHELIOMA;

CARCINOMA, BASAL CELL; CARCINOMA, SKIN APPENDAGE; HUMANS; IMMUNOENZYME TECHNIQUES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77951753697     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181b7fc76     Document Type: Article

References (23)

1. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29 encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1988;2:305-316.
2. Yang A, McLeon F. p63 and p73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol. 2000;3:199-207.
3. Yang A, Kaghad M, Caput D, et al. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 2002;18:90-95.
4. Levrero M, De Laurenzi V, Constanzo A, et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci. 2000; 113:1661-1670.
5. Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A. 2001;98:3156-3161.
6. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708-713.
7. Yang A, Schweitzer R, Sun D. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714-718.
8. Parsa R, Yang A, McLeon F, et al. Association of p63 in proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol. 1999;113:1099-1105.
9. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in normal and tumor tissues. Clin Cancer Res. 2002;8:494-501.
10. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 4/6 and cytokeratin 14 and 51 in normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virch Arch. 2003;443:122-132.
11. Barbareschi M, Pecciarini L, Cangi MG. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of human breast. Am J Surg Pathol. 2002;25:1054-1062.
12. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol. 2002;9: 280-289.
13. Reis-Filho JS, Torio B, Albergaria A, et al. p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol. 2002;29:517-523. (Pubitemid 35193295)
14. Tsujita-Kyutoku M, Kuichi K, Danbara N, et al. p63 expression in normal human epidermis and epidermal appendages and their tumors. J Cutan Pathol. 2003;30:11-17.
15. Ivan D, Diwan H, Prieto VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol. 2005;18:137-142.
16. Dotto JE, Glusac EJ. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2006;33:413-417.
17. Emanuel P, Wang B, Wu M, et al. p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol. 2005;18:645-650.
18. Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol. 2007;34:782-787.
19. Hoang MP, Dresser KA, Kapur P, et al. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol. 2008;21:178-185.
20. Abesamis-Cubillan E, Shabrawi-Cailen L, LeBoit PE. Merkel cells and sclerosing epithelial neoplasms. Am J Dermatopathol. 2000;22:311.
21. Katona TM, Perkins SM, Billings SD. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? J Cutan Pathol. 2008;35:174-179.
22. Goldstein DJ, Barr RJ, Santa Cruz DJ. Microcystic adnexal carcinoma: a distinct clinicopathologic entity. Cancer. 1982;50:566-572.
23. Chiller K, Passaro D, Scheuller M, et al. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. 2000;136:1355-1359.